Cosyntropin for the Treatment of Refractory Postdural Puncture Headache in Pediatric Patients: A Retrospective Review.
Postdural puncture headache is a challenging complication of diagnostic, therapeutic, and unintentional lumbar puncture. Literature evidence supports cosyntropin as a viable noninvasive therapy for adults who have failed conservative management, but pediatric data is limited. The purpose of this retrospective chart review is to describe the use of intravenous cosyntropin for refractory pediatric postdural puncture headache at a single free-standing tertiary care pediatric hospital. Patients who had received cosyntropin were identified. Charts were retrospectively reviewed for indication, dosing information, efficacy and side effects. Response was defined as fifty percent reduction in pain score, with a secondary efficacy measure of time to discharge after first dose. Over a five-year period, 26 patients received 37 doses of cosyntropin. Dosing ranged from 5-15▒mcg/kg (median 10.4▒mcg/kg). There was significant reduction in pain scores after the first dose of cosyntropin (P=0.008). Eighty-one percent of patients (n=21) achieved either 50% reduction in pain or discharge within 24 hours after the first dose. Median time to 50% pain reduction in 13 patients who achieved it prior to discharge was five hours (range 1-30▒h). Median time to discharge after first dose was 20 hours (range 2-72▒h). Ten patients received more than one dose of cosyntropin. Three patients required epidural blood patch. No adverse effects related to treatment were identified. This study suggests that while further research is warranted, cosyntropin is a potential alternative to epidural blood patch for pediatric patients with postdural puncture headache who fail conservative management.